These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10368645)

  • 1. Chemopreventive activity of a C-glucuronide analog of N-(4-hydroxyphenyl) retinamide-O-glucuronide against mammary tumor development and growth.
    Abou-Issa HM; Alshafie GA; Curley RW; Wong MF; Clagett-Dame M; Repa JJ; Sikri V
    Anticancer Res; 1999; 19(2A):999-1004. PubMed ID: 10368645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
    Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
    Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapeutic evaluation of N-(4-hydroxyphenyl) retinamide-O-glucuronide in the rat mammary tumor model.
    Abou-Issa H; Curley RW; Panigot MJ; Tanagho SN; Sidhu BS; Alshafie GA
    Anticancer Res; 1997; 17(5A):3335-9. PubMed ID: 9413168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
    Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
    Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative chemopreventive activity of ibuprofen and N-(4-hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas.
    Alshafie GA; Harris RE; Robertson FM; Parrett ML; Ross M; Abou-Issa H
    Anticancer Res; 1999; 19(4B):3031-6. PubMed ID: 10652588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic evaluation of 4-hydroxybenzylretinone (4-HBR), a nonhydrolyzable C-linked analog of N-(4-hydroxyphenyl) retinamide (4-HPR) against mammary carcinogenesis.
    Abou-Issa H; Curley RW; Alshafie GA; Weiss KL; Clagett-Dame M; Chapman JS; Mershon SM
    Anticancer Res; 2001; 21(6A):3839-44. PubMed ID: 11911255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mammary tumor growth by a novel nontoxic retinoid: chemotherapeutic evaluation of a C-linked analog of 4-HPR-glucuronide.
    Alshafie GA; Walker JR; Curley RW; Clagett-Dame M; Highland MA; Nieves NJ; Stonerock LA; Abou-Issa H
    Anticancer Res; 2005; 25(3c):2391-8. PubMed ID: 16082771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.
    Abou-Issa HM; Alshafie GA; Seibert K; Koki AT; Masferrer JL; Harris RE
    Anticancer Res; 2001; 21(5):3425-32. PubMed ID: 11848504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of short-term administration of N-(4-hydroxyphenyl)-all-trans-retinamide on chemically induced mammary tumors.
    Silverman J; Katayama S; Radok P; Levenstein MJ; Weisburger JH
    Nutr Cancer; 1983; 4(3):186-91. PubMed ID: 6221232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis.
    Abou-Issa H; Moeschberger M; el-Masry W; Tejwani S; Curley RW; Webb TE
    Anticancer Res; 1995; 15(3):805-10. PubMed ID: 7645962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and preliminary chemotherapeutic evaluation of the fully C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
    Walker JR; Alshafie G; Nieves N; Ahrens J; Clagett-Dame M; Abou-Issa H; Curley RW
    Bioorg Med Chem; 2006 May; 14(9):3038-48. PubMed ID: 16412653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism of growth inhibition of mammary carcinomas by glucarate and the glucarate: retinoid combination.
    Webb TE; Abou-Issa H; Stromberg PC; Curley RC; Nguyen MH
    Anticancer Res; 1993; 13(6A):2095-9. PubMed ID: 8297119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative efficacy of the opioid antagonist, naltrexone, on the initiation and promotion phases of rat mammary carcinogenesis.
    Koo KL; Tejwani GA; Abou-Issa H
    Anticancer Res; 1996; 16(4A):1893-8. PubMed ID: 8712718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinoids as chemopreventive agents for breast cancer.
    Moon RC; Mehta RG; Detrisac CJ
    Cancer Detect Prev; 1992; 16(1):73-9. PubMed ID: 1551141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
    Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
    Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of DMBA-initiated rat mammary tumour development by 1-O-hexyl-2,3,5-trimethylhydroquinone, phenylethyl isothiocyanate, and novel synthetic ascorbic acid derivatives.
    Futakuchi M; Hirose M; Miki T; Tanaka H; Ozaki M; Shirai T
    Eur J Cancer Prev; 1998 Apr; 7(2):153-9. PubMed ID: 9818778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy.
    McCormick DL; Mehta RG; Thompson CA; Dinger N; Caldwell JA; Moon RC
    Cancer Res; 1982 Feb; 42(2):508-12. PubMed ID: 6459843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats.
    Hakkak R; Korourian S; Shelnutt SR; Lensing S; Ronis MJ; Badger TM
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):113-7. PubMed ID: 10667471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model.
    Saarinen NM; Huovinen R; Wärri A; Mäkelä SI; Valentín-Blasini L; Needham L; Eckerman C; Collan YU; Santti R
    Nutr Cancer; 2001; 41(1-2):82-90. PubMed ID: 12094633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumor promoting potential of luteolin against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
    Samy RP; Gopalakrishnakone P; Ignacimuthu S
    Chem Biol Interact; 2006 Dec; 164(1-2):1-14. PubMed ID: 17064676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.